U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07726329) titled 'Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma' on June 04, 2020.
Brief Summary: The prognosis of advanced hepatocellular carcinoma is poor. In this study, the eligible patients will be treated by tumor antigen-pulsed autologous dendritic cells and followed by TACE. The end points are to see tumor response and patient survival.
Study Start Date: July 01, 2019
Study Type: INTERVENTIONAL
Condition:
Liver Neoplasms
Intervention:
BIOLOGICAL: dendritic cells
autologous dendritic cell vaccination
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Chang Gung Memorial Hospital
Information provided by (Responsib...